CMS-D008 is a novel siRNA therapy administered by subcutaneous injection that targets and inhibits INHBE. By loweringthe level of INHBE and its encoded Activin E protein, it can block Activin E-ALK7 signaling and reduces fat accumulation effectively. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Preclinical studies suggestedthat CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile, demonstrating potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. CMS-D008will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice […]
Learn More
Recently, S&P Global, an internationally authoritative rating agency, has released the Sustainability Yearbook 2026 (the “Yearbook”). China Medical System (“CMS” or the “Group”) has stood out among 9,200 participating companies and successfully secured a place in the Yearbook, with a 2025 Corporate Sustainability Assessment (CSA) score of 66, surpassing 92% of global peers. This marks the second consecutive year that CMS has earned this international honor. Source: S&P Global Guided by its long-term ESG strategic objectives, CMS has deeply integrated the concept of sustainable development into its strategic decision-making and daily operations. The Group is driven by the dual engines of in-house R&D and collaborative R&D, continuously enhancing the accessibility and affordability of healthcare services and working to narrow health disparities across different regions and populations. Concurrently, we actively fulfill our corporate social responsibilities, leveraging innovative biotechnology to drive industry advancement and contribute to the sustained improvement of social well-being. Our sustainability performance has also been recognized by multiple authoritative rating agencies: MSCI ESG Rating maintained at “AA”; the Hong Kong […]
Learn More
Ruxolitinib phosphate cream, as the first and only targeted drug approved in China for the treatment of vitiligo, marked a key milestone in its expansion into multiple therapeutic areas with the acceptance of its NDA for the additional indication of AD. The NDA has been included in the Priority Review List based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”which is expected to accelerate the Product’s review process for marketing approval. Ruxolitinib phosphate cream has achieved positive results in the China Phase III clinical trial for AD: At Week 8, 63.0% of subjects achieved IGA 0/1, with ≥2 grades of reduction from baseline (vs. 9.2% for placebo, P < 0.001); 78.0% of subjects achieved EASI 75 (vs. 15.4% for placebo, P < 0.001). Overall, ruxolitinib phosphate cream was safe and well-tolerated. For AD, Dermavon has developed a comprehensive “treatment […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
